Ursolic acid promotes colorectal cancer cell apoptosis and inhibits cell proliferation via modulation of multiple signaling pathways

International Journal of Oncology

Volumn 43, Issue 4, 2013, Pages 1235-1243

  Lin, Jiumao ^a,b   Chen, Youqin ^c   Wei, Lihui ^a,b   Shen, Aling ^a,b   Sferra, Thomas J ^c   Hong, Zhenfeng ^a   Peng, Jun ^a,b  

^a Academy of Integrative Medicine Biomedical Research Center   (China)

^b FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Colorectal cancer; Multi target based agent; Signaling pathway; Ursoloic acid

Indexed keywords

ANTINEOPLASTIC AGENT; URSOLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMANS; MICE; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRITERPENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84882373206     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2040     Document Type: Article

References (33)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Gustin DM and Brenner DE: Chemoprevention of colon cancer: current status and future prospects. Cancer Metastasis Rev 21: 323-348, 2002.
3. Gorlick R and Bertino JR: Drug resistance in colon cancer. Semin Oncol 26: 606-611, 1999.
4. Longley DB, Allen WL and Johnston PG: Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Biochim Biophys Acta 1766: 184-196, 2006.
5. Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, Dey S and Sung B: Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann NY Acad Sci 1171: 59-76, 2009.
6. Zhong Z, Wen Z and Darnell J: Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264: 95-98, 1994.
7. Bromberg J and Wang TC: Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 15: 79-80, 2009.
8. Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Inoue K, Nagayasu T and Sekine I: Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. Oncol Rep 15: 1445-1451, 2006.
9. Lin Q, Lai R, Chirieac LR, Li C, Thomazy VA, Grammatikakis I, Rassidakis GZ, Zhang W, Fujio Y, Kunisada K, Hamilton SR and Amin HM: Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol 167: 969-980, 2005.
10. Xiong H, Zhang Z, Tian X, Sun D, Liang Q, Zhang Y, Lu R, Chen Y and Fang J: Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia 10: 287-297, 2008.
11. Sebolt-Leopold JS: Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 19: 6594-6599, 2000.
12. Seger R and Krebs EG: The MAPK signaling cascade. FASEB J 9: 726-735, 1995.
13. Taupin D and Podolski DK: Mitogen-activated protein kinase activation regulates intestinal epithelial differentiation. Gastroenterology 116: 1072-1080, 1999.
14. Wang X, Wang Q, Hu W and Evers BM: Regulation of phorbol estermediated TRAF1 induction in human colon cancer cells through a PKC/RAF/ERK/NF-kappaB- dependent pathway. Oncogene 23: 1885-1895, 2004.
15. Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310, 2007.
16. Schwartsmann G, Di Leone LP, Dal Pizzol F and Roesler R: MAPK pathway activation in colorectal cancer: a therapeutic opportunity for GRP receptor antagonists. Lancet Oncol 6: 444-445, 2005.
17. Fang JY and Richardson BC: The MAPK signalling pathways and colorectal cancer. Lancet Oncol 6: 322-327, 2005.
18. Ma XH and Wang ZW: Anticancer drug discovery in the future: an evolutionary perspective. Drug Discov Today 14: 1136-1142, 2009.
19. Gordaliza M: Natural products as leads to anticancer drugs. Clin Transl Oncol 9: 767-776, 2007.
20. Lin JM, Chen YQ, Wei LH, Chen XZ, Xu W, Hong ZF, Sferra TJ and Peng J: Hedyotis Diffusa Willd extract induces apoptosis via activation of the mitochondrion-dependent pathway in human colon carcinoma cells. Int J Oncol 37: 1331-1338, 2010.
21. Cai QY, Lin JM, Wei LH, Zhang L, Wang LL, Zhan YZ, Zeng JW, Xu W, Shen AL, Hong ZF and Peng J: Hedyotis diffusa Willd inhibits colorectal cancer growth in vivo via inhibition of STAT3 signaling pathway. Int J Mol Sci 13: 6117-6128, 2012.
22. Wei LH, Chen YQ, Lin JM, Zhao JY, Chen XZ, Xu W, Liu XX, Sferra TJ and Peng J: Scutellaria Barbata D. Don induces apoptosis of human colon carcinoma cell via activation of the mitochondrion-dependent pathway. J Med Plants Res 5: 1962-1970, 2011.
23. Zheng LP, Chen YQ, Lin W, Zhuang QC, Chen XZ, Xu W, Liu XX, Peng J and Sferra TJ: Spica Prunellae extract promotes mitochondrion-dependent apoptosis in a human colon carcinoma cell line. Afr J Pharm Pharmacol 5: 327-335, 2011.
24. Ikeda Y, Murakami A and Ohigashi H: Ursolic acid: an anti-and pro-inflammatory triterpenoid. Mol Nutr Food Res 52: 26-42, 2008.
25. Xavier CP, Lima CF, Preto A, Seruca R, Fernandes-Ferreira M and Pereira-Wilson C: Luteolin, quercetin and ursolic acid are potent inhibitors of proliferation and inducers of apoptosis in both KRAS and BRAF mutated human colorectal cancer cells. Cancer Lett 281: 162-170, 2009.
26. Andersson D, Liu JJ, Nilsson A and Duan RD: Ursolic acid inhibits proliferation and stimulates apoptosis in HT29 cells following activation of alkaline sphingomyelinase. Anticancer Res 23: 3317-3322, 2003.
27. Adams J and Cory S: The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26: 1324-1337, 2007.
28. Youle RJ and Strasser A: The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59, 2008.
29. Nurse P: Ordering S phase and M phase in the cell cycle. Cell 79: 547-550, 1994.
30. Morgan DO: Principles of CDK regulation. Nature 374: 131-134, 1995.
31. Zafonte BT, Hulit J, Amanatullah DF, Albanese C, Wang C, Rosen E, Reutens A, Sparano JA, Lisanti MP and Pestell RG: Cell-cycle dysregulation in breast cancer: breast cancer therapies targeting the cell cycle. Front Biosci 5: D938-D961, 2000.
32. Kouraklis G, Theocharis S, Vamvakas P, Vagianos C, Glinavou A, Giaginis C and Sioka C: Cyclin D1 and Rb protein expression and their correlation with prognosis in patients with colon cancer. World J Surg Oncol 4: 5, 2006.
33. Domagala W, Welcker M, Chosia M, Karbowniczek M, Harezga B, Bartkova J, Bartek J and Osborn M: p21/WAF1/Cip1 expression in invasive ductal breast carcinoma: Relationship to p53, proliferation rate, and survival at 5 years. Virchows Arch 439: 132-140, 2001.